CA2652392C - Culture method for obtaining a clonal population of antigen-specific b cells - Google Patents

Culture method for obtaining a clonal population of antigen-specific b cells Download PDF

Info

Publication number
CA2652392C
CA2652392C CA2652392A CA2652392A CA2652392C CA 2652392 C CA2652392 C CA 2652392C CA 2652392 A CA2652392 A CA 2652392A CA 2652392 A CA2652392 A CA 2652392A CA 2652392 C CA2652392 C CA 2652392C
Authority
CA
Canada
Prior art keywords
antigen
cells
antibody
cell
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2652392A
Other languages
English (en)
French (fr)
Other versions
CA2652392A1 (en
Inventor
Leon Garcia-Martinez
Anne Elisabeth Carvalho Jensen
Ethan Ojala
John Latham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2652392(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of CA2652392A1 publication Critical patent/CA2652392A1/en
Application granted granted Critical
Publication of CA2652392C publication Critical patent/CA2652392C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2652392A 2006-05-19 2007-05-21 Culture method for obtaining a clonal population of antigen-specific b cells Expired - Fee Related CA2652392C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80141206P 2006-05-19 2006-05-19
US60/801,412 2006-05-19
PCT/US2007/011980 WO2008045140A1 (en) 2006-05-19 2007-05-21 Culture method for obtaining a clonal population of antigen-specific b cells

Publications (2)

Publication Number Publication Date
CA2652392A1 CA2652392A1 (en) 2008-04-17
CA2652392C true CA2652392C (en) 2017-10-10

Family

ID=39283142

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652392A Expired - Fee Related CA2652392C (en) 2006-05-19 2007-05-21 Culture method for obtaining a clonal population of antigen-specific b cells

Country Status (12)

Country Link
US (3) US20070269868A1 (enExample)
EP (1) EP2021463B1 (enExample)
JP (1) JP5607357B2 (enExample)
CN (1) CN101600793B (enExample)
AU (1) AU2007307324B2 (enExample)
CA (1) CA2652392C (enExample)
DK (1) DK2021463T3 (enExample)
IL (1) IL195285A (enExample)
MX (1) MX2008014692A (enExample)
NO (1) NO20084835L (enExample)
NZ (1) NZ572807A (enExample)
WO (1) WO2008045140A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
MX2011005411A (es) * 2008-11-25 2011-06-16 Alder Biopharmaceuticals Inc Anticuerpos de il-6 y uso de los mismos.
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
WO2012133572A1 (ja) 2011-03-30 2012-10-04 国立大学法人富山大学 形質細胞または形質芽細胞の選択方法、目的抗原特異的な抗体の製造方法、新規モノクローナル抗体
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
WO2013000982A1 (en) * 2011-06-27 2013-01-03 Vivalis Method for screening cells
EP2761015A4 (en) * 2011-09-28 2015-09-02 Cb Biotechnologies Inc IDENTIFICATION OF ANTIGEN-SPECIFIC ADAPTIVE IMMUNE REACTIONS BY ARM-PCR AND HIGH-BY-STEP SEQUENCING
KR102069394B1 (ko) 2011-11-23 2020-01-22 에프. 호프만-라 로슈 아게 Ｃｄ40ｌ 발현 포유류 세포 및 그의 용도
JP2015500655A (ja) 2011-12-21 2015-01-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 同起源の抗体可変領域遺伝子セグメントをクローニングおよび発現させるための迅速な方法
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2917238A1 (en) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
AU2013344992A1 (en) * 2012-11-13 2015-05-14 Genentech, Inc. Enrichment of antigen-specific plasmablasts
JP2016506974A (ja) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
ES2834113T3 (es) 2013-03-15 2021-06-16 H Lundbeck As Purificación de anticuerpos y monitorización de la pureza
US20140287952A1 (en) * 2013-03-15 2014-09-25 Alderbio Holdings Llc Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
US10138294B2 (en) 2013-03-15 2018-11-27 Alderbio Holdings Llc Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
CN104232577B (zh) * 2013-06-20 2017-12-01 中国人民解放军军事医学科学院基础医学研究所 一种获得自身反应性b细胞的方法
WO2015003122A2 (en) 2013-07-03 2015-01-08 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
US10047157B2 (en) 2014-12-19 2018-08-14 Alder Biopharmaceuticals, Inc. Humanized anti-ACTH antibodies and use thereof
EP3271393A4 (en) * 2015-03-18 2018-10-31 Epitomics, Inc. High throughput monoclonal antibody generation by b cell panning and proliferation
EP3305325B1 (en) 2015-06-04 2025-07-30 National Center of Neurology and Psychiatry Mental illness therapeutic agent having il-6 inhibitor as active ingredient
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
JP7026634B2 (ja) 2016-03-30 2022-02-28 エフ．ホフマン－ラ ロシュ アーゲー Ｂ細胞培養法
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
CN106350485B (zh) * 2016-08-24 2020-02-21 杭州百凌生物科技有限公司 一种快速高效分离单个抗原特异性b细胞的方法
JP6916884B2 (ja) 2017-01-02 2021-08-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ細胞培養法
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
EP3625332B1 (en) 2017-05-19 2022-02-02 F. Hoffmann-La Roche AG Method for the production of thymocyte supernatant
US11125757B2 (en) * 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
CN111417719B (zh) 2017-11-30 2023-08-29 豪夫迈·罗氏有限公司 B细胞培养方法
JP2021525070A (ja) * 2018-05-18 2021-09-24 チャン ザッカーバーグ バイオハブ， インコーポレイテッド ヒト由来のアレルゲン特異的抗体を単離する方法およびその使用
EP4004044A1 (en) 2019-07-24 2022-06-01 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2022004620A1 (ja) * 2020-06-29 2022-01-06 株式会社Npt 抗原特異的抗体産生細胞を含む組成物の製造方法、ワクチン組成物の製造方法、細胞分離キットおよびワクチン組成物
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
US20240228595A1 (en) * 2021-05-11 2024-07-11 Yale University Methods for Monoclonal Antibody Generation
EP4590704A1 (en) 2022-09-21 2025-07-30 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7796291A (en) * 1990-05-04 1991-11-27 Baxter Diagnostics Inc. High affinity antibodies to small peptides
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ZA919299B (en) * 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US20050033031A1 (en) * 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
US20060263353A1 (en) 2003-08-20 2006-11-23 Lawson Alastair D G Methods for obtaining antibodies
EP1658498A1 (en) 2003-08-20 2006-05-24 Celltech R & D Limited Methods for obtaining antibodies
CN1871259A (zh) * 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005020924A2 (en) * 2003-08-29 2005-03-10 Centocor, Inc. A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
ES2393555T3 (es) * 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
GB0412973D0 (en) 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells
US20060051348A1 (en) * 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
CN101048426A (zh) * 2004-10-22 2007-10-03 金克克国际有限公司 分离人抗体
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
WO2007038746A2 (en) * 2005-09-28 2007-04-05 The University Of Chicago Versatile vectors for expression of foreign proteins in photosynthetic bacteria

Also Published As

Publication number Publication date
US20130316353A1 (en) 2013-11-28
CA2652392A1 (en) 2008-04-17
US20120141982A1 (en) 2012-06-07
NZ572807A (en) 2011-10-28
WO2008045140A1 (en) 2008-04-17
AU2007307324A1 (en) 2008-04-17
EP2021463A4 (en) 2009-09-02
CN101600793B (zh) 2013-06-26
MX2008014692A (es) 2009-08-18
IL195285A0 (en) 2011-08-01
IL195285A (en) 2012-07-31
CN101600793A (zh) 2009-12-09
AU2007307324B2 (en) 2013-08-15
US20070269868A1 (en) 2007-11-22
JP2009537176A (ja) 2009-10-29
JP5607357B2 (ja) 2014-10-15
NO20084835L (no) 2009-02-16
DK2021463T3 (en) 2017-01-16
EP2021463A1 (en) 2009-02-11
EP2021463B1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
AU2007307324B2 (en) Culture method for obtaining a clonal population of antigen-specific B cells
JP6466397B2 (ja) 抗原特異的ｂ細胞の同定及び単離ならびに所望の抗原に対する抗体作製のプロトコール
EP2724157B1 (en) Method for screening cells
CN107428827A (zh) 通过b细胞淘选和增殖高通量产生单克隆抗体
KR20200003235A (ko) arm-PCR 및 고속 처리 서열 분석을 이용한 항원 특이적 후천성 면역 반응의 확인
HK1127372B (en) Culture method for obtaining a clonal population of antigen-specific b cells
HK1127372A (en) Culture method for obtaining a clonal population of antigen-specific b cells
CN117866086B (zh) 结合人微囊蛋白-1的单克隆抗体及应用
CN107109423A (zh) 用于生产双特异性抗体的细胞的制备和挑选
JP5435539B2 (ja) 抗体産生細胞の活性化ペプチド
WO2022162009A1 (en) Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) Method for rapid identification of cross-reactive and/or rare antibodies
Zhai et al. Monoclonal Antibody Development Technology for Important Human Diseases
JP5246859B2 (ja) 抗体産生細胞の誘導又は活性化方法
JP5164161B2 (ja) インビトロ免疫法
CN121005774A (zh) 小鼠肝炎病毒抗体及其应用
HK40031675B (zh) B细胞培养方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210521